Galderma (UK) awards sole-preferred distributor status for its aesthetics portfolio in the UK and Ireland to Med-fx
Med-fx Ltd has been identified as the potential sole-preferred distributor for the aesthetics portfolio of Galderma (U.K.) Limited in the UK and Ireland, following a review of the company’s distribution arrangements.
The appointment follows a robust tender process that Galderma (U.K.) Limited announced to distributors in early March. Under the new sole-preferred distributor arrangement, Med-fx could be awarded a contract to service all customers who purchase Galderma products marketed under the Azzalure and Restylane brands in the United Kingdom and the Republic of Ireland.
Subject to contract, the new proposals would come into effect on the 8th September 2019. The new proposition will be mapped out over the coming months. In the interim, and outside of the new arrangement, existing distributors will continue to be able to purchase and sell Galderma products and services.
The refined distribution model will allow Galderma and Med-fx to deliver a more customer-centric proposition, offering healthcare professionals an enhanced level of tailored support.
Toby Cooper, Medical Solutions Business Unit Head, Galderma UK & Ireland said, “We’re very pleased to be working with Med-fx on developing an improved proposition for our customers. They have a strong market standing and share our vision of being healthcare professionals’ trusted partners in making a positive difference in the lives of clients.
“I’m confident that working with Med-fx on a refined distribution model will allow us to enrich the relationships we have with our customers and we look forward to sharing details on the new proposition as soon as possible.”
Paul Adams – Managing Director, Med FX & Dental Directory Group Companies, added, “I am delighted to have the opportunity to partner with Galderma (UK Ltd) on an exciting journey to jointly develop a market leading solution for healthcare professionals.”
